Targets › FAP
55 programs from 46 companies in 63 trials: 37 Phase 1, 21 Phase 2, 4 Phase 3, 1 Phase 4; Oncology, Cardiovascular, Respiratory; next expected readout Dec 2026.
Cell surface glycoprotein serine protease that participates in extracellular matrix degradation and involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences, on substrate such as…. (UniProt, Q12884)
Open in Phaseline: the race on FAP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Medical Center Groningen | 68Ga-FAPI gallium-68-labeled fibroblast activation protein inhibitor | FAP | Phase 4 | Peyronie's Disease | Aug 2027 |
| SOFIE | [18F]FAPI-74 FAP-targeting radioactive diagnostic agent for PET imaging | FAP | Phase 3 | Esophageal Cancer; Pancreatic Ductal Adenocarcinoma (PDAC) | Aug 2027 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | [68Ga]Ga-CTR-FAPI Fibroblast activation protein (FAP) inhibitor radiopharmaceutical for PET-CT imaging | FAP | Phase 3 | Medullary Thyroid Carcinoma | Sep 2028 |
| National Heart, Lung, and Blood Institute (NHLBI) | [18F]FAPI-74 Fibroblast activation protein (FAP)-targeted PET tracer | FAP | Phase 3 | Allogeneic Stem Cell Transplantation | May 2031 |
| John O. Prior | [68Ga]Ga-FAPI-46 PET/CT FAP-targeted PET imaging agent | FAP | Phase 2 | Head and Neck Squamous Cell Carcinoma HNSCC | Dec 2026 |
| University of Wisconsin, Madison | Ga-FAPI-46 Fibroblast activation protein (FAP) inhibitor | FAP | Phase 2 | Prostate Cancer Metastatic Disease | Jan 2027 |
| Barbara Malene Fischer | [68Ga]Ga-FAPI-46 Fibroblast activation protein (FAP) inhibitor PET tracer | FAP | Phase 2 | Pancreatic Cancer, Adult; Malignant Melanoma Stage IV | Jan 2027 |
| Maastricht University Medical Center | 68Ga-FAPI-46 Fibroblast activation protein (FAP) inhibitor | FAP | Phase 2 | Breast Cancer | Mar 2027 |
| Aalborg University Hospital | [68Ga]Ga-FAPI-46 PET/CT Fibroblast Activation Protein (FAP) inhibitor labeled with Gallium-68 for positron emissio | FAP | Phase 2 | Pleural Mesothelioma | Apr 2027 |
| Mayo Clinic | Gallium Ga 68 FAPi-46 Radiopharmaceutical targeting fibroblast activation protein (FAP) on cancer-associated fib | FAP | Phase 2 | Localized Pancreatic Adenocarcinoma | Jun 2027 |
| AstraZeneca | AZD2389 FAP inhibitor | FAP | Phase 2 | Liver Fibrosis | Jul 2027 |
| Mara Veenstra, MD | [18F]F-FAPI PET-CT Fibroblast activation protein (FAP) inhibitor PET-CT imaging agent | FAP | Phase 2 | Cholangiocarcinoma | Sep 2027 |
| University of Wisconsin, Madison | FAPI tracer Fibroblast activation protein (FAP) inhibitor radiotracer | FAP | Phase 2 | Fibrosis Lung | Sep 2027 |
| Nantes University Hospital | [68Ga]Ga-FAPI-46 Fibroblast activation protein (FAP) PET tracer labeled with gallium-68 | FAP | Phase 2 | Transthyretin Cardiac Amyloidosis | Oct 2027 |
| KU Leuven | [18F]AlF-FAPI-74 Fibroblast activation protein (FAP) inhibitor PET tracer | FAP | Phase 2 | Oesophageal Cancer | Dec 2027 |
| Peking Union Medical College Hospital | [¹⁸F]AlF-NOTA-FAPI-04 Fibroblast activation protein (FAP) inhibitor PET imaging agent | FAP | Phase 2 | Nonischemic Cardiomyopathy | Dec 2027 |
| Blue Earth Diagnostics | [68Ga]BED003 Fibroblast activation protein (FAP) targeting PET imaging agent | FAP | Phase 2 | Colorectal Cancer | Feb 2028 |
| Universität Münster | [68Ga]Ga-FAPI-46 Fibroblast activation protein (FAP) targeted positron emission tomography (PET) imaging ag | FAP | Phase 2 | Carcinoma, Intraductal, Noninfiltrating | Mar 2028 |
| University Hospital, Bordeaux | 68Ga-FAPI-46 Fibroblast activation protein inhibitor (FAPI) PET imaging agent | FAP | Phase 2 | Cholangiocarcinoma | Mar 2028 |
| National Cancer Institute (NCI) | [18F]FAPI-74 Fibroblast activation protein (FAP) inhibitor PET tracer | FAP | Phase 2 | Sarcoma | Jun 2028 |
| Institut Curie | 68Ga-FAPI-46 Gallium-68-labeled fibroblast activation protein inhibitor used as PET radiotracer | FAP | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | Aug 2029 |
| Turku University Hospital | 18F-FAPI-74 fibroblast activation protein inhibitor PET tracer | FAP | Phase 2 | Positron Emission Tomography | – |
| Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd. | Technetium [99mTc]-H7ND injection Radiolabeled fibroblast activation protein (FAP) inhibitor | FAP | Phase 2 | Solid Tumor | – |
| Turku University Hospital | [F-18]FAPI-74 Fibroblast activation protein (FAP) inhibitor PET tracer | FAP | Phase 2 | Colon Cancer | – |
| Xiaorong Sun | [225Ac]Ac-FAPI-XT (XT117) alpha-emitting radiopharmaceutical targeting fibroblast activation protein (FAP) | FAP | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Xinlu Wang | [177Lu]Lu-XT117 Lu-177 conjugate targeting FAP (fibroblast activation protein) | FAP | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Ruimin Wang | [177Lu]Lu-XT117 FAP-targeted radiopharmaceutical therapy (Lu-177 beta emitter conjugated to FAP-targeting | FAP | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| SHAOYAN LIU | 177Lu-CTR-FAPI Fibroblast activation protein inhibitor-targeted radiopharmaceutical | FAP | Phase 1 | Thyroid Cancer | Dec 2026 |
| First Affiliated Hospital of Fujian Medical University | 177Lu-JH040182 FAP-targeted radiopharmaceutical (fibroblast activation protein ligand labeled with luteti | FAP | Phase 1 | Patients With Advanced Metastatic FAP-Positive Tumors | Dec 2026 |
| Thomas Hope | Gallium-68 labelled (68Ga-) FAP-2286 Radiolabeled peptidomimetic that binds to Fibroblast Activation Protein (FAP) for PET imag | FAP | Phase 1 | Solid Tumors, Adult | Dec 2026 |
| Tomsk National Research Medical Center of the Russian Academy of Sciences | [99mTc]Tc-HYNIC-FAPI Fibroblast activation protein (FAP) targeting agent labeled with technetium-99m | FAP | Phase 1 | Lung Cancer (Locally Advanced or Metastatic) | Dec 2026 |
| Peking Union Medical College Hospital | [68Ga]Ga-NI-FAPI-04 Fibroblast activation protein (FAP)-targeting PET imaging agent | FAP | Phase 1 | Tumor | Feb 2027 |
| Beijing Biotech | EB-MF-CAR-NK-01 Dual-target CAR-NK cells recognizing mesothelin-positive tumor cells and FAP-positive stro | MSLN, FAP | Phase 1 | Malignant Pleural Mesotheliomas | Mar 2027 |
| Jonsson Comprehensive Cancer Center | Gallium Ga 68 FAPi-46 FAP-targeting PET tracer | FAP | Phase 1 | Metastatic Malignant Neoplasm in the Prostate Gland; Bladder Carcinoma; Anal Carcinoma | May 2027 |
| Yi Tian | 68Ga-FXX489 (NNS309) FAP-targeting radiotracer for PET imaging | FAP | Phase 1 | Tumor | Jul 2027 |
| BioInvent International | BI-1607 FAP inhibitor (fibroblast activation protein inhibitor) | FAP | Phase 1 | Melanoma Metastatic | Jul 2027 |
| Abramson Cancer Center at Penn Medicine | [F-18]-FAPI-74 FAP-targeted PET imaging agent; positron-emitting radiopharmaceutical for selective measur | FAP | Phase 1 | Fibrosis (Morphologic Abnormality) | Jul 2027 |
| Avacta Life Sciences | AVA6000 FAP-activated doxorubicin prodrug | FAP | Phase 1 | Salivary Gland Tumor | Aug 2027 |
| Chengdu New Radiomedicine Technology | 177Lu-NRT6020 Injection FAP-targeting radiopharmaceutical for radionuclide therapy | FAP | Phase 1 | Solid Tumor Malignancy | Oct 2027 |
| Chengdu New Radiomedicine Technology | 68Ga-NRT6020 Injection FAP-targeting radiopharmaceutical for PET imaging | FAP | Phase 1 | Solid Tumor Malignancy | Oct 2027 |
| Oncomatryx Biopharma | OMTX705 anti-FAP antibody-drug conjugate | FAP | Phase 1 | Advanced Solid Tumor; Pancreatic Adenocarcinoma Metastatic | Dec 2027 |
| Novartis | 177Lu-FAP-2286 FAP-targeted peptide radioligand (177Lu-labeled) | FAP | Phase 1 | Solid Tumor | Dec 2027 |
| Peking Union Medical College Hospital | Al18F-NOTA-FAPI-04 18F-labeled fibroblast activation protein (FAP) inhibitor PET imaging agent | FAP | Phase 1 | Hyperthyroidism, Autoimmune | Dec 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | FAP immunosuppressive CAR-DC FAP-targeted chimeric antigen receptor dendritic cell therapy | FAP | Phase 1 | Dilated Cardiomyopathy (DCM) | Dec 2027 |
| Ratio Therapeutics | [Ac225]RTX-2358 Actinium-225 alpha emitter conjugated to FAP-targeting antibody | FAP | Phase 1 | Advanced Soft Tissue Sarcoma | Jan 2028 |
| Blue Earth Diagnostics | [18F]FPyQCP Fibroblast activation protein (FAP) inhibitor positron emission tomography tracer | FAP | Phase 1 | Colorectal Cancer | Jan 2028 |
| Perspective Therapeutics | [203Pb]Pb-PSV359 FAP-targeting radiopharmaceutical with lead-203 for imaging | FAP | Phase 1 | Pancreatic Ductal Adenocarcinoma | Jan 2028 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | autologous FAP-targeted immunosuppressive CAR-DCs (iCDC) FAP-targeted chimeric antigen receptor dendritic cell therapy | FAP | Phase 1 | Ischemic Cardiomyopathy | Apr 2028 |
| Philogen | [177Lu]Lu-OncoFAP-23 Radioligand targeting fibroblast activation protein (FAP) | FAP | Phase 1 | FAP | May 2028 |
| Avacta Life Sciences | AVA6103 FAP-activated Exatecan | FAP | Phase 1 | Vulvar Adenocarcinoma | Jan 2029 |
| Karolinska University Hospital | 68Ga-FAPI-46 Fibroblast Activation Protein inhibitor labeled with Gallium-68 for PET imaging | FAP | Phase 1 | Pancreatic Neoplasms | Mar 2029 |
| Immunome | 177Lu-IM-3050 FAP-directed radiopharmaceutical | FAP | Phase 1 | Solid Malignancies | Dec 2029 |
| Lantheus Medical Imaging | 64Cu-LNTH-1363S FAP inhibitor radiolabeled with Copper-64 (64Cu) for PET/CT imaging | FAP | Phase 1 | Metastatic Sarcoma | – |
| Peking Union Medical College Hospital | 68Ga-FAPI Fibroblast activation protein (FAP) inhibitor | FAP | Phase 1 | Sjogren's Syndrome; Pulmonary Fibrosis | – |
| National University Hospital, Singapore | 68Gallium-FAPI-46 PET/MRI Fibroblast Activation Protein (FAP)-targeting PET/MRI tracer | FAP | Phase 1 | Hepatocellular Carcinoma | – |
Advanced Solid Tumor (4) Solid Tumor (2) Solid Tumor Malignancy (2) Cholangiocarcinoma (2) Pancreatic Ductal Adenocarcinoma (PDAC) (2) Tumor (2) Colorectal Cancer (2) Dilated Cardiomyopathy (DCM) (2) Solid Tumors, Adult (2) Prostate Cancer Metastatic Disease (1) Oesophageal Cancer (1) Pancreatic Neoplasms (1)
small molecule (42), mixed (3), protein or peptide (2)
Peking Union Medical College Hospital (4) University of Wisconsin, Madison (2) Chengdu New Radiomedicine Technology (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (2) Avacta Life Sciences (2) Turku University Hospital (2) Blue Earth Diagnostics (2) KU Leuven (1) Karolinska University Hospital (1) Universität Münster (1) Xinlu Wang (1) Novartis (1) Jonsson Comprehensive Cancer Center (1) Mara Veenstra, MD (1) Nantes University Hospital (1) Xiaorong Sun (1) Barbara Malene Fischer (1) Ratio Therapeutics (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Mayo Clinic (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.